FDA approved program headed to liquidation auction Print E-mail
By Staff and Wire Reports   
Friday, 16 October 2009 03:00

Even as they were announcing their FDA Approval of a Physician-Sponsored IND for Fourth 6-month Open Label Extension of PRX-03140 for Alzheimer's Disease Patients, EPIX Pharmaceuticals, Inc. (OTC:EPIX) plans to quietly wind down operations after a hard fought battle to keep the company afloat.

The Lexington, Mass.-based company’s officials said Epix was unable to raise enough money or enter into a partnership in time to remain a going concern. Months ago, it had filed paperwork to provide for an orderly liquidation of its assets.

Back in late July, EPIX Pharmaceuticals entered into an Assignment for the Benefit of Creditors in accordance with Massachusetts state law. The purpose of the Assignment is to conclude their operations and provide for an orderly liquidation of all of its assets.

The Assignment is a common law business liquidation mechanism under Massachusetts law that is an alternative to a formal bankruptcy proceeding.

Under the terms of the Assignment, the Company transferred all of its assets to an assignee for orderly liquidation and distribution of the proceeds to the Company's creditors.

The PRX-03140 program which received the FDA approval will be sold at auction on Wednesday, October 21 at 3 pm. EDT.

 




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter